IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v18y2017i8d10.1007_s10198-016-0844-8.html
   My bibliography  Save this article

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

Author

Listed:
  • Hayley Bennett

    (HEOR, Health Economics and Outcomes Research Ltd)

  • Jason Gordon

    (HEOR, Health Economics and Outcomes Research Ltd
    University of Adelaide)

  • Beverley Jones

    (HEOR, Health Economics and Outcomes Research Ltd)

  • Thomas Ward

    (HEOR, Health Economics and Outcomes Research Ltd)

  • Samantha Webster

    (HEOR, Health Economics and Outcomes Research Ltd)

  • Anupama Kalsekar

    (Bristol-Myers Squibb Pharmaceuticals Ltd)

  • Yong Yuan

    (Bristol-Myers Squibb Pharmaceuticals Ltd)

  • Michael Brenner

    (UK HEOR, Bristol-Myers Squibb Pharmaceuticals Ltd)

  • Phil McEwan

    (HEOR, Health Economics and Outcomes Research Ltd
    Swansea University)

Abstract

Background Hepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates. Methods An established model of HCV disease transmission and progression was used to quantify the impact of treatment uptake (10–100%), within the PWID population, on the cost-effectiveness of a DAA regimen versus pre-DAA standard of care, conducted using daclatasvir plus sofosbuvir in the UK setting as an illustrative example. Results The consequences of reduced disease transmission due to treatment were associated with additional net monetary benefit of £24,304–£90,559 per patient treated at £20,000/QALY, when 10–100% of eligible patients receive treatment with 100% efficacy. Dependent on patient genotype, the cost-effectiveness of HCV treatment using daclatasvir plus sofosbuvir improved by 36–79% versus conventional analysis, at 10–100% treatment uptake in the PWID population. Conclusions The estimated cost-effectiveness of HCV treatment was shown to improve as more patients are treated, suggesting that the value of DAA regimens to the NHS could be enhanced by improved treatment uptake rates among PWID. However, the challenge for the future will lie in achieving increased rates of treatment uptake, particularly in the PWID population.

Suggested Citation

  • Hayley Bennett & Jason Gordon & Beverley Jones & Thomas Ward & Samantha Webster & Anupama Kalsekar & Yong Yuan & Michael Brenner & Phil McEwan, 2017. "Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 1001-1011, November.
    • Handle: RePEc:spr:eujhec:v:18:y:2017:i:8:d:10.1007_s10198-016-0844-8
    DOI: 10.1007/s10198-016-0844-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-016-0844-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-016-0844-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Phil McEwan & Thomas Ward & Hayley Bennett & Anupama Kalsekar & Samantha Webster & Michael Brenner & Yong Yuan, 2015. "Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(1), pages 1-16, January.
    2. Phil McEwan & Ray Kim & Yong Yuan, 2013. "Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 53-63, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Umberto Restelli & Alfredo Alberti & Adriano Lazzarin & Marzia Bonfanti & Carmela Nappi & Davide Croce, 2018. "Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affecte," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 37-44, January.
    2. Do Young Kim & Kwang-Hyub Han & Byungyool Jun & Tae Hyun Kim & Sohee Park & Thomas Ward & Samantha Webster & Phil McEwan, 2017. "Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea," PLOS ONE, Public Library of Science, vol. 12(1), pages 1-16, January.
    3. Constanza L Vargas & Manuel A Espinoza & Andrés Giglio & Alejandro Soza, 2015. "Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-16, November.
    4. Yun Lu & Xiuze Jin & Cheng-a-xin Duan & Feng Chang, 2018. "Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China," PLOS ONE, Public Library of Science, vol. 13(4), pages 1-12, April.
    5. Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    6. Phil McEwan & Thomas Ward & Hayley Bennett & Anupama Kalsekar & Samantha Webster & Michael Brenner & Yong Yuan, 2015. "Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(1), pages 1-16, January.
    7. Bassem Asker & Raghad Jawad & Rabah Asreah & Haydar Jamal & Ahmed Jassem & Muslim Abdelkareem Inaya & Hiwa Abou Baker & Sam Kozma & Eid Mansour & Bryony McNamara & Ryan Miller & Oliver Darlington & Ph, 2021. "Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment," PharmacoEconomics, Springer, vol. 39(11), pages 1327-1341, November.

    More about this item

    Keywords

    Hepatitis C virus; Disease transmission; Cost-effectiveness; PWID;
    All these keywords.

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:18:y:2017:i:8:d:10.1007_s10198-016-0844-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.